Next-generation of selective histone deacetylase inhibitors. Issue 34 (24th June 2019)

• Record Type: Journal Article
• Authors: Yang, Feifei; Zhao, Na; Ge, Di; Chen, Yihua
• Is Part Of: RSC advances. Volume 9:Issue 34(2019)
• Page Start: 19571
• Page End: 19583
• Publication Date: 2019-06-24
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c9ra02985k
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. Abstract : Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side effects. At present, the next-generation HDACis are mainly focused on being class- or isoform-selective which can provide improved risk–benefit profiles compared to non-selective inhibitors. Because of the rapid development in next-generation HDACis, it is necessary to have an updated and state-of-the-art overview. Here, we summarize the strategies and achievements of the selective HDACis.